26 May 2013
Keywords: important, xoma, activities, relating, its, neuprex, rbpi-23
Article | 02 May 1994
Xoma's activities in 1994 relating to its Neuprex (rBPI-23) sepsis
product should bring the company back into the forefront of investors'
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
2 May 1994
9 May 1994
24 May 2013
© 2013 thepharmaletter.com